Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous adipose tissue-derived mesenchymal stem cells (Bukwang Pharmaceutical)
- Development stage
- Unknown
- Lead developer
- Bukwang Pharmaceutical
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intrathecal
01
Overview
Autologous adipose tissue-derived mesenchymal stem cells (AD-MSCs) is a cell therapy developed by Bukwang Pharmaceutical for the treatment of spinal cord injury. The therapy involves harvesting a patient's own adipose tissue, isolating the mesenchymal stem cells, and expanding them ex vivo before re-administering them to the patient via intrathecal injection. These stem cells are thought to exert therapeutic effects through paracrine signaling, secreting a variety of neurotrophic and immunomodulatory factors that reduce neuroinflammation, promote the survival of existing neurons, and potentially facilitate axonal regeneration and remyelination at the site of injury. A Phase 1 clinical trial was conducted in South Korea to evaluate the safety and preliminary efficacy of this approach in patients with spinal cord injuries.
- Other names
- AD-MSCsautologous adipose-derived mesenchymal stem cellsBukwang AD-MSC
Beyond the preview
Go deeper on autologous adipose tissue-derived mesenchymal stem cells (Bukwang Pharmaceutical).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous adipose tissue-derived mesenchymal stem cells (Bukwang Pharmaceutical).